Single-center experience of patients with interstitial lung diseases during the early days of the COVID-19 pandemic
| Autor: | J. Guiot, M. Henket, A.N. Frix, M. Delvaux, A. Denis, L. Giltay, M. Thys, F. Gester, M. Moutschen, J.L. Corhay, R. Louis, A. Ancion, A. Bouquegneau, C. Bovy, G. Darcis, J.O. Defraigne, B. Duysinx, A. Ghuysen, A. Gilbert, V. Heinen, B. Lambermont, O. Malaise, M. Martin, B. Misset, D. Nguyen Dang, J. Piazza, J. Szecel, F. Vaillant, H. Van Cauwenberge, C. Von Frenckell, L. Vroonen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Interstitial lung diseases Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Single Center 03 medical and health sciences Global population 0302 clinical medicine Internal medicine Pandemic medicine Humans In patient 030212 general & internal medicine Pandemics Retrospective Studies Lung business.industry SARS-CoV-2 Clinical epidemiology COVID-19 respiratory system respiratory tract diseases body regions medicine.anatomical_structure 030228 respiratory system Cohort Lung fibrosis business Lung Diseases Interstitial Rapid Communication |
| Zdroj: | Respiratory Investigation |
| ISSN: | 2212-5353 2212-5345 |
| Popis: | Introduction Patients with interstitial lung diseases (ILD) can be suspected to be at risk of experiencing a rapid flare-up due to COVID-19. However, no specific data are currently available for these patients. Methods We retrospectively analyzed a cohort of 401 patients with ILD and determined the proportion of patients hospitalized for proven severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and specific symptoms of COVID-19. Results We found that 1% of patients (n = 4) were hospitalized (1 in ICU) for COVID-19. In total, 310 of the 401 patients answered the phone call. Only 33 patients (0.08%) experienced specific symptoms of SARS-CoV-2 infection. Conclusion Our study did not demonstrate any increased occurrence of severe COVID-19 in ILD patients compared to the global population. Based on our findings, we could not make any conclusion on the incidence rate of SARS-CoV-2 infection in patients with ILDs, or on the overall outcome of immunocompromised patients affected by COVID-19. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect